Drugs in Dev. Gastroenterology
Phase II
Australia 
Lead Product(s) : Bovine Colostrum
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : US Department of Defense
Deal Size : $3.4 million
Deal Type : Funding
Immuron Announces Positive Travelan® Results for US Phase 3 Trials
Details : The funding aims to support Immuron advance their clinical development of Travelan (bovine colostrum), which is being evaluated in Phase II clinical trial studies for moderate to severe diarrhea.
Product Name : Travelan
Product Type : Dietary Supplement
Upfront Cash : Undisclosed
July 03, 2024
Lead Product(s) : Bovine Colostrum
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : US Department of Defense
Deal Size : $3.4 million
Deal Type : Funding
Lead Product(s) : Travelan
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : US Department of Defense | Naval Medical Research Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Clinical Study to Assess the Efficacy of IMM-124E (Travelan®) in a Controlled Human Infection Model
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
July 06, 2023
Lead Product(s) : Travelan
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : US Department of Defense | Naval Medical Research Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bovine Colostrum
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Immuron Receives European Patent on Drug Composition to Treat Travelers’ Diarrhea
Details : Travelan (IMM-124E) is a colostrum-based product containing high levels of anti-E.coli-LPS IgG, and might limit exposure to bacterial endotoxins treatment reduced the DSS-induced serum levels of lipopolysaccharide-binding protein, indicating reduced syst...
Product Name : Travelan
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
January 13, 2022
Lead Product(s) : Bovine Colostrum
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
